Disclosed is the use of the compounds represented by formula (I) in the preparation of a medicament against tumor angiogenesis, wherein R 1 and R 2 are each independently C 1 -C 8 alkylidene group or C 2 -C 8 alkenylidene group A 1 and A 2 are each independently aryl, isoaryl, or aryl or isoaryl optionally substituted by halogen, -CN, -NO 2 , -OH, -SH, -OR 3 , -SR 3 , -R 3 , -R 3 -OR 4 , -C(O)R 3 , -S(O)R 3 , -S(O) 2 R 3 , -NR 4 R 5 , -C(O)OR 3 , -C(O)NR 4 R 5 , -O(O)CR 4 , -S(O)CR 4 or -NR 4 (O)CR 5 , wherein R 3 is C 1 -C 4 alkyl, R 4 and R 5 are each independently hydrogen, C 1 -C 4 alkyl, aryl or substituted aryl and X and Y are each independently oxygen and the compound of formula (I) does not include phenethyl caffeate.
